» Articles » PMID: 9519815

Distinct Interleukin-1beta-converting Enzyme Family Proteases Mediate Cisplatin- and Staurosporine-induced Apoptosis of Mouse Proximal Tubule Cells

Overview
Journal Life Sci
Publisher Elsevier
Date 1998 Mar 31
PMID 9519815
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Interleukin-1beta converting enzyme (ICE) family proteases (caspases) are known to be implicated as important effectors of apoptotic pathways. The purpose of this study was to elucidate the role of ICE family proteases in apoptosis of mouse cells derived from the terminal proximal tubule (S3) treated with cisplatin, an anti-tumor drug, or staurosporine, a protein kinase C inhibitor. For this purpose, we measured the activities of ICE family proteases and examined the effects of tetrapeptide and viral ICE family protease inhibitors on the activities of ICE family proteases in and the degree of apoptosis of S3 cells treated with cisplatin and staurosporine. RT-PCR analysis revealed that S3 cells as well as mouse kidney express mRNA for ICE and CPP32, an ICE family protease. Results of enzymatic analysis, determination the degree of DNA fragmentation and cytotoxicity test suggest that CPP32 mediates cisplatin-induced apoptosis of S3 cells, whereas ICE family proteases other than CPP32 mediate staurosporine-induced apoptosis of S3 cells. In conclusion, distinct ICE family proteases mediate apoptosis of mouse proximal tubule cells depending on the stimuli to which the cells are exposed.

Citing Articles

Effect of Intravenous Glutamine on Caspase-12 Expression in the Apoptosis of the Glomerular Epithelial Cells of Male Rats Exposed to Cisplatin.

Fakhrinnisa T, Susilo I, Mustika A, Sofyan M Asian Pac J Cancer Prev. 2021; 22(2):457-462.

PMID: 33639660 PMC: 8190340. DOI: 10.31557/APJCP.2021.22.2.457.


Mechanisms of Cisplatin nephrotoxicity.

Miller R, Tadagavadi R, Ramesh G, Reeves W Toxins (Basel). 2011; 2(11):2490-518.

PMID: 22069563 PMC: 3153174. DOI: 10.3390/toxins2112490.


Cisplatin nephrotoxicity: molecular mechanisms.

Hanigan M, Devarajan P Cancer Ther. 2008; 1:47-61.

PMID: 18185852 PMC: 2180401.